Pfizer has been investing billions of dollars to buy up several companies that treat conditions caused by Covid mRNA vaccines.
In 2017 a former vice president of Pfizer blew the whistle and said that pharmaceutical companies intentionally design vaccines to keep the public in a state of illness to profit from the treatments of vaccine-induced illnesses.
Pfizer’s acquisitions of other pharmaceutical companies since the rollout of its covid vaccine seem to indicate this is indeed the case.
In 2021, Pfizer’s acquisition of Arena Pharmaceuticals raised eyebrows.
The purchase price seemed disproportionate to the market size of the drug they acquired – a drug that is a potential therapy for all kinds of immuno-inflammatory diseases, including inflammation of the heart. As we know, myocarditis began to skyrocket after the rollout of Pfizer’s mRNA vaccines.
In 2023, Pfizer purchased Seagen Pharmaceuticals, known for its cancer drugs.
Was this because of the connection between the mRNA injections and “turbo cancers”?
In 2022, Pfizer purchased Global Blood Therapeutics for its drug to treat sickle cell disease, again for an amount that seemed disproportionate to the profit the company could make off the drug considering how many people have the disease.
Does Pfizer know something we don’t? Will we see a blood cell disease epidemic as well?
This article from 2017 reports on Dr. Peter Rost, a former vice president of Pfizer and a pharmaceutical industry whistleblower.
He is the author of ‘The Whistleblower, Confessions of a Healthcare Hitman’, and at the time was talking about how deadly the HPV vaccine was.
Dr. Rost claimed that pharmaceutical companies intentionally design vaccines to keep the public in a state of illness for purposes of perpetual treatments.
That was seven years ago, and never has the evil of Pfizer been more apparent.
In January 2024, “the powers that be” declared that the new coronavirus variant would likely cause a higher risk of heart problems.
This time, they presented research from RIKEN, Japan’s largest scientific institute, funded nearly entirely by the Japanese government.
However, RIKEN also accepts “donations from individuals and corporations for the enhancement and development of research.”
They even have a page where donors can send a direct credit card donation.
In 2019, RIKEN had a budget of $900 million, yet they apparently still need credit card donations.
What type of corporations work with RIKEN?
Corporations like Bayer work with RIKEN, like in the drug discovery collaboration they’ve been jointly working on for about five years.
In December 2021, Pfizer announced they would buy Arena Pharmaceuticals.
Pfizer had its eye on etrasimod, Arena’s drug for ulcerative colitis (“UC”).
The drug was approved by the FDA in October 2023, and Pfizer now markets it as VELSIPITY™.
Pfizer’s website says in the press release that “UC is a chronic and often debilitating condition that affects an estimated 1.25 million people in the United States.”
That’s a lot of people, but is it enough of a market to drive Pfizer to buy Arena at a 100% premium, a $6.7 billion cash deal?
Pfizer sped the development of etrasimod because the drug is a potential therapy for all kinds of immuno-inflammatory diseases, including inflammation of the heart.
Part of the deal was that Pfizer acquired all Arena assets in gastroenterology, dermatology, and cardiology.
The first links between the COVID-19 mRNA jabs and myocarditis began to be reported in July 2021.
In December 2021, Pfizer entered into a formal agreement to purchase Arena, and by March 2022, it was a done deal.
Incredibly, myocarditis incidents began skyrocketing shortly thereafter.
In one example from a May 2022 article, emergency cardiac arrest calls for young adults strongly correlated with the vaccine rollout of doses 1 and 2 in Israel, one of the most injected countries in the world.
An FDA-sponsored study looked at health records of children from December 2020 to June 2022 and found incidences of myocarditis and pericarditis to be high enough to trigger a safety signal in 12 to 17-year-olds.
The timeframe from the injection to seeking cardiac care for myocarditis or pericarditis was 6.8 days.
In a literature review from 2020 to 2022, males were approximately seven times more likely than females to present myocarditis or pericarditis.
Another recent study concluded that a booster dose is associated with increased myocarditis risk in adolescents and young adults.
Cancer
In early 2023, Pfizer announced another huge deal with the purchase of Seagen Pharmaceuticals.
Seagen is known for its pipeline of cancer drugs, and Pfizer really wanted that pipeline because they spent $43 billion on the deal. Pfizer Chairman and CEO Albert Bourla described it as “acquiring the goose that is laying the golden eggs.”
Once again, the purchase begs the question: Is this business prowess on the part of Pfizer, or is it all planned?
The concept of “turbo cancer” was introduced in January 2023 when fact-checkers across the internet began reporting that any connection between the mRNA injections and turbo cancer was false. By summer, physicians started describing turbo cancers as the new pandemic and scientists started to provide reasoning for the sudden and aggressive cancers that oncologists were witnessing.
They seemed to start after a covid-19 booster dose in all cases. Soon, articles like THIS one were commonplace, with physicians professing they had never seen cancers with this form of aggression who were often dead within a few months, weeks or sometimes even days.
Bourla himself said that the world is experiencing a new type of cancer epidemic, which may explain the Seagen purchase. Seagen works with antibody-drug conjugate (“ADC”) technology, which uses monoclonal antibodies made to seek out cancer cells and deliver a drug to those cells while sparing the surrounding tissue. Bourla called the ADC technology “one of the greatest technologies to battle cancer” and said they were “very much like the mRNA for vaccines.”
Interestingly, Pfizer created the first ADC, Mylotarg, but had to remove it from the market in 2010 after studies showed the drug was more toxic than chemotherapy.
Bourla said the Seagen acquisition will “dramatically change the oncology presence of Pfizer, making it one of a kind. Seagen’s cancer therapy will bring cancer treatment to the world at a scale that has not been seen before.”
Problem. Reaction. Solution.
Unadulterated Greed
Pfizer was literally flooded with cash after 2021.
Pfizer’s revenues in 2021 were double their revenues from 2020 ($81.3 billion). In 2022, they bought Biohaven Pharmaceuticals for $11.6 billion to gain access to the company’s migraine drug. That same year, they also purchased Global Blood Therapeutics to gain access to the company’s sickle cell drug Oxbryta. But only approximately 100,000 Americans suffer from sickle cell; how can they make $3 billion off this drug? What does Pfizer know that the rest of us don’t? Will we see a blood cell disease epidemic as well?
Some analysts note that, ultimately, Pfizer may go bankrupt with all the lawsuits on the horizon. Will Pfizer go the way of Purdue Pharma, a company where greed and dishonesty allowed it to continue marketing harmful products to the public? Just as with Purdue, will Pfizer lose its legal protections when the millions of vaccine injury claims and charges of fraud land on Bourla’s desk?
The days of huge revenues from covid-19 products have passed. The US government is returning $3.5 billion of unused Paxlovid treatments, and Pfizer is facing revenue losses from many patent expirations and unfulfilled government contracts worldwide.
Vigilant News noted that older, more experienced vaccine companies such as GSK did not enter the covid-19 vaccine fray. That looks like it was a wise choice. However, they no doubt got paid well for sitting this one out.
Today, Pfizer’s stock is far less valuable than it was just a few years ago, despite the flashy acquisitions of companies like Arena and Seagen and the billions of dollars made from the covid death injections. In the last year, Pfizer has underperformed by 35% compared to the overall pharmaceuticals index.
We can only hope Pfizer – and all other players such as doctors, nurses, pharmacists, politicians and governments will soon pay dearly for their folly. That is the heart of the matter.
